Skip to content

Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)

A Retrospective, Non-interventional, Epidemiologic Study of the Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02104219
Enrollment
32
Registered
2014-04-04
Start date
2014-03-31
Completion date
2014-09-30
Last updated
2019-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypophosphatasia (HPP)

Keywords

Hypophosphatasia, HPP, bone disease, Soft Bones, low Alkaline Phosphatase, genetic metabolic disorder, alkaline phosphatase, tissue non-specific alkaline phosphatase, rickets, osteomalacia

Brief summary

The purpose of this study is to characterize the natural history of HPP in patients with Juvenile-onset HPP.

Detailed description

Hypophosphatasia (HPP) is a life-threatening, genetic, and ultra-rare metabolic disease characterized by defective bone mineralization and impaired phosphate and calcium regulation that can lead to progressive damage to multiple vital organs, including destruction and deformity of bones, profound muscle weakness, seizures, impaired renal function, and respiratory failure. There are no approved disease-modifying treatments for patients with this disease. There is also limited data available on the natural course of this disease over time, particularly in patients with the juvenile-onset form.

Interventions

None listed

Sponsors

Alexion Pharmaceuticals, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
5 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Documented informed consent unless patient is deceased * Patients with Juvenile-onset HPP, defined as documented onset of first signs/symptoms at ≥ 6 months to ˂18 years * Documented diagnosis of HPP as indicated by skeletal manifestations and low alkaline phosphatase or genotyping

Exclusion criteria

* Received treatment with asfotase alfa in the ENB-006-09 study and/or currently enrolled in the ENB-008-10 study * Received other treatment and/or intervention to treat HPP up to 15 years old * Other clinically significant disease

Design outcomes

Primary

MeasureTime frameDescription
Radiographic Global Impression of Change - RGI-CBetween Baseline (earliest available, complete, and readable x-ray set) and all available, readable post-Baseline x-ray sets during the period of patients' aged 5 to 15 years, inclusive.The RGI-C scale is a 7-point ordinal scale that is used to evaluate musculoskeletal characteristics of HPP (eg, metaphyseal fraying, demineralization of distal metaphyses). The scores range from -3 (severe worsening) to +3 (complete or near-complete healing).

Secondary

MeasureTime frameDescription
Change in Height Z-score From Baseline to Last AssessmentAny available growth data during the period of patients' aged 5 to 15 years, inclusive. Baseline is the earliest available assessment while post baselines are time points after Baseline during the defined age period.Height measurements were assigned to Z-scores which were calculated using the Centers for Disease Control and Prevention (CDC) 2000 growth charts and methodology. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z-scores indicate a better outcome.
Change in Weight Z-score From Baseline to Last AssessmentAny available growth data during the period of patients' aged 5 to 15 years, inclusive. Baseline is the earliest available assessment while Post baselines are time points after Baseline during the defined age period.Weight measurements were assigned a Z-score which was calculated using the Centers for Disease Control and Prevention (CDC) 2000 growth charts and methodology. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z-scores indicate a better outcome.

Other

MeasureTime frameDescription
Rickets Severity Sale - RSSAny available data during the period of patients' aged 5 to 15 years, inclusive. Baseline is the earliest available assessment value during the period.The RSS is a 10-point scale, developed for nutritional rickets, that evaluates the degree of metaphyseal cupping and fraying and the proportion of growth plate affected (10 points = severe cupping/fraying, 0 points = absence of cupping/fraying).

Countries

Australia, Canada, France, Netherlands, Russia, Turkey (Türkiye), United Kingdom, United States

Participant flow

Recruitment details

Patients were enrolled between March 2014 and September 2014. Fifty-four patients were screened and 32 patients were enrolled at 15 centers across the United States, Canada, Australia, Turkey, The Netherlands, and the United Kingdom.

Participants by arm

ArmCount
Patients Diagnosed With Juvenile-onset HPP
Patients diagnosed with juvenile-onset HPP (ie, documented onset of first signs/symptoms of HPP at ≥ 6 months to \< 18 years of age).
32
Total32

Baseline characteristics

CharacteristicPatients Diagnosed With Juvenile-onset HPP
Age, Customized47 months
STANDARD_DEVIATION 32.21
Growth Measured by Height Z-score-0.86 Z-score
Growth Measured by Weight Z-score-0.86 Z-score
Race/Ethnicity, Customized
Unknown or Not Reported
1 participants
Race/Ethnicity, Customized
White
31 participants
Region of Enrollment
Australia
2 participants
Region of Enrollment
Europe
5 participants
Region of Enrollment
North America
25 participants
Rickets Severity Scale - RSS1.00 units on a scale
Sex: Female, Male
Female
10 Participants
Sex: Female, Male
Male
22 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 0
serious
Total, serious adverse events
0 / 0

Outcome results

Primary

Radiographic Global Impression of Change - RGI-C

The RGI-C scale is a 7-point ordinal scale that is used to evaluate musculoskeletal characteristics of HPP (eg, metaphyseal fraying, demineralization of distal metaphyses). The scores range from -3 (severe worsening) to +3 (complete or near-complete healing).

Time frame: Between Baseline (earliest available, complete, and readable x-ray set) and all available, readable post-Baseline x-ray sets during the period of patients' aged 5 to 15 years, inclusive.

Population: Patients diagnosed with juvenile-onset HPP.

ArmMeasureValue (MEDIAN)
Patients Diagnosed With Juvenile-onset HPPRadiographic Global Impression of Change - RGI-C0.33 units on a scale
Comparison: Pairs of radiographs were centrally evaluated by 3 independent, blinded pediatric radiologists trained in the assessment of the skeletal manifestations of HPP. The mean RGI-C score across the 3 radiologists was calculated and served as the patient's RGI-C score for a specific time pointp-value: 0.0755Sign test
Secondary

Change in Height Z-score From Baseline to Last Assessment

Height measurements were assigned to Z-scores which were calculated using the Centers for Disease Control and Prevention (CDC) 2000 growth charts and methodology. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z-scores indicate a better outcome.

Time frame: Any available growth data during the period of patients' aged 5 to 15 years, inclusive. Baseline is the earliest available assessment while post baselines are time points after Baseline during the defined age period.

ArmMeasureValue (MEDIAN)
Patients Diagnosed With Juvenile-onset HPPChange in Height Z-score From Baseline to Last Assessment-0.05 Z-score
Comparison: The earliest documented height measurement that was abstracted within the period from 5 to 15 years of age, inclusive, was defined as the baseline height. Height measurements were assigned to Z-scores calculated using Centers for Disease Control and Prevention 2000 growth charts and methodology. Changes in height Z-score from Baseline were computed by subtracting baseline height Z-score from post baseline height Z-scores. The post baseline time points were grouped by time intervals.p-value: 0.6344Sign test
Secondary

Change in Weight Z-score From Baseline to Last Assessment

Weight measurements were assigned a Z-score which was calculated using the Centers for Disease Control and Prevention (CDC) 2000 growth charts and methodology. The Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. Higher Z-scores indicate a better outcome.

Time frame: Any available growth data during the period of patients' aged 5 to 15 years, inclusive. Baseline is the earliest available assessment while Post baselines are time points after Baseline during the defined age period.

Population: All patients who met all of the inclusion and none of the exclusion criteria were defined as the enrolled population, which was also the analysis population.

ArmMeasureValue (MEDIAN)
Patients Diagnosed With Juvenile-onset HPPChange in Weight Z-score From Baseline to Last Assessment0.12 Z-score
Comparison: The earliest documented weight measurement that was abstracted within the period from 5 to 15 years of age, inclusive, was defined as the baseline weight. Weight measurements were assigned to Z-scores calculated using Centers for Disease Control and Prevention 2000 growth charts and methodology. Changes in weight Z-score from Baseline were computed by subtracting baseline weight Z-score from post baseline weight Z-scores. The post baseline time points were grouped by time intervals.p-value: 0.452Sign test
Other Pre-specified

Rickets Severity Sale - RSS

The RSS is a 10-point scale, developed for nutritional rickets, that evaluates the degree of metaphyseal cupping and fraying and the proportion of growth plate affected (10 points = severe cupping/fraying, 0 points = absence of cupping/fraying).

Time frame: Any available data during the period of patients' aged 5 to 15 years, inclusive. Baseline is the earliest available assessment value during the period.

Population: All patients who met all of the inclusion and none of the exclusion criteria were defined as the enrolled population, which was also the analysis population.

ArmMeasureValue (MEDIAN)
Patients Diagnosed With Juvenile-onset HPPRickets Severity Sale - RSS0.00 units on a scale
Comparison: The Baseline x-ray set defined for RGI-C, which was compared with its subsequent x-ray sets, was also used as the Baseline x-ray set for the RSS reading. Changes from Baseline were computed based on this baseline RSS score, and postbaseline time points were grouped by intervals of time from Baseline.p-value: 0.4545Sign test

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026